{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:16:17Z","timestamp":1790237777502,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1097\/md.0000000000004947","type":"journal-article","created":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T09:54:33Z","timestamp":1476870873000},"page":"e4947","source":"Crossref","is-referenced-by-count":51,"title":["Thiazolidinediones for nonalcoholic steatohepatitis"],"prefix":"10.1097","volume":"95","author":[{"given":"Lingling","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210309","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"R2-10-20210309","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology"},{"key":"R3-10-20210309","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cld.2012.03.005","article-title":"Nonalcoholic fatty liver disease","volume":"16","author":"Paredes","year":"2012","journal-title":"Clin Liver Dis"},{"key":"R4-10-20210309","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"R5-10-20210309","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.beem.2013.02.002","article-title":"Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae","volume":"27","author":"Karlas","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R6-10-20210309","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2036.2012.05196.x","article-title":"Review article: non-alcoholic fatty liver disease and osteoporosis: clinical and molecular crosstalk","volume":"36","author":"Yilmaz","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R7-10-20210309","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1017\/S0029665110000030","article-title":"Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome","volume":"69","author":"Moore","year":"2010","journal-title":"Proc Nutr Soc"},{"key":"R8-10-20210309","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1590\/S0004-28032012000100015","article-title":"Metabolic syndrome and risk factors for non-alcoholic fatty liver disease","volume":"49","author":"Souza","year":"2012","journal-title":"Arq Gastroenterol"},{"key":"R9-10-20210309","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"Ratziu","year":"2010","journal-title":"J Hepatol"},{"key":"R10-10-20210309","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R11-10-20210309","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"key":"R12-10-20210309","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1053\/j.gastro.2011.06.061","article-title":"Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States","volume":"141","author":"Charlton","year":"2011","journal-title":"Gastroenterology"},{"key":"R13-10-20210309","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1440-1746.2007.04952.x","article-title":"What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?","volume":"22","author":"Fan","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"R14-10-20210309","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2337\/diacare.28.6.1518","article-title":"Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease","volume":"28","author":"Bloomgarden","year":"2005","journal-title":"Diabetes Care"},{"key":"R15-10-20210309","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/gast.2001.27126","article-title":"Nonalcoholic steatohepatitis","volume":"121","author":"Reid","year":"2001","journal-title":"Gastroenterology"},{"key":"R16-10-20210309","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.25772","article-title":"Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis","volume":"56","author":"Loomba","year":"2012","journal-title":"Hepatology"},{"key":"R17-10-20210309","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"key":"R18-10-20210309","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00125-008-1135-4","article-title":"Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?","volume":"51","author":"Targher","year":"2008","journal-title":"Diabetologia"},{"key":"R19-10-20210309","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Engl J Med"},{"key":"R20-10-20210309","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/hep.1840380427","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"R21-10-20210309","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis","volume":"39","author":"Promrat","year":"2004","journal-title":"Hepatology"},{"key":"R22-10-20210309","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jhep.2005.11.030","article-title":"Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat?","volume":"44","author":"Larter","year":"2006","journal-title":"J Hepatol"},{"key":"R23-10-20210309","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"R24-10-20210309","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2036.2008.03723.x","article-title":"Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis","volume":"28","author":"Idilman","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R25-10-20210309","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jhep.2011.03.016","article-title":"The role of thiazolidinediones in non-alcoholic steatohepatitis: a systematic review and meta analysis","volume":"55","author":"Mahady","year":"2011","journal-title":"J Hepatol"},{"key":"R27-10-20210309","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R28-10-20210309","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"R29-10-20210309","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"R30-10-20210309","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"R31-10-20210309","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/hep.21661","article-title":"The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis","volume":"46","author":"Lutchman","year":"2007","journal-title":"Hepatology"},{"key":"R32-10-20210309","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cld.2007.02.001","article-title":"Medical treatment of non-alcoholic steatohepatitis","volume":"11","author":"Kadayifci","year":"2007","journal-title":"Clin Liver Dis"},{"key":"R33-10-20210309","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R34-10-20210309","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/hep.27999","article-title":"Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis","volume":"62","author":"Singh","year":"2015","journal-title":"Hepatology"},{"key":"R35-10-20210309","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000323928","article-title":"Pathophysiology of non-alcoholic steatohepatitis and basis for treatment","volume":"29","author":"Pinzani","year":"2011","journal-title":"Dig Dis"},{"key":"R36-10-20210309","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000282084","article-title":"Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases","volume":"28","author":"Powell","year":"2010","journal-title":"Dig Dis"},{"key":"R37-10-20210309","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.20920","article-title":"Insulin resistance: a metabolic pathway to chronic liver disease","volume":"42","author":"Bugianesi","year":"2005","journal-title":"Hepatology"},{"key":"R38-10-20210309","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1007\/s001250100031","article-title":"Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients","volume":"44","author":"Miyazaki","year":"2001","journal-title":"Diabetologia"},{"key":"R39-10-20210309","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2337\/diacare.24.4.710","article-title":"Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone","volume":"24","author":"Miyazaki","year":"2001","journal-title":"Diabetes Care"},{"key":"R40-10-20210309","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1006\/bbrc.2000.3868","article-title":"Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone","volume":"278","author":"Sakamoto","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"R41-10-20210309","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/diacare.25.2.376","article-title":"Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients","volume":"25","author":"Yang","year":"2002","journal-title":"Diabetes Care"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000004947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:34:09Z","timestamp":1620959649000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201610180-00010"}},"subtitle":["A meta-analysis of randomized clinical trials"],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":40,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000004947","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}